BACKGROUND: Heparanase up-regulation has been correlated with reduced postoperative survival in various cancers. METHODS: Heparanase expression was analyzed in 60 consenting tongue (mobile) cancer patients by means of immunohistochemistry. Heparanase levels were also analyzed in the saliva of both healthy controls and tongue cancer patients using a novel heparanase enzyme-linked immunosorbent assay method. RESULTS: Heparanase staining was positive (>0) in 92% and negative (=0) in 8% of the tumors and staining intensity correlated with tumor size and tumor stage. Moreover, the survival probability of patients negative for heparanase (=0) at 60 months was 100%, compared with only 41% for patients positive for heparanase (>0), suggesting that heparanase may serve as a prognostic factor for this malignancy and an attractive target for anticancer drug development. Heparanase was detected in the saliva of healthy controls and the mean concentration was determined as 119 +/- 37 pg/mL. Importantly, a nearly 3-fold increase of heparanase levels was detected in saliva collected from tongue cancer patients (334 +/- 69 pg/mL), a difference that is statistically highly significant (P = .004). CONCLUSIONS: These findings support heparanase up-regulation in tongue cancer and raise the possibility of using this simple test as a diagnostic tool to monitor tongue cancer progression and response to treatment. 2007 American Cancer Society
BACKGROUND:Heparanase up-regulation has been correlated with reduced postoperative survival in various cancers. METHODS:Heparanase expression was analyzed in 60 consenting tongue (mobile) cancerpatients by means of immunohistochemistry. Heparanase levels were also analyzed in the saliva of both healthy controls and tongue cancerpatients using a novel heparanase enzyme-linked immunosorbent assay method. RESULTS:Heparanase staining was positive (>0) in 92% and negative (=0) in 8% of the tumors and staining intensity correlated with tumor size and tumor stage. Moreover, the survival probability of patients negative for heparanase (=0) at 60 months was 100%, compared with only 41% for patients positive for heparanase (>0), suggesting that heparanase may serve as a prognostic factor for this malignancy and an attractive target for anticancer drug development. Heparanase was detected in the saliva of healthy controls and the mean concentration was determined as 119 +/- 37 pg/mL. Importantly, a nearly 3-fold increase of heparanase levels was detected in saliva collected from tongue cancerpatients (334 +/- 69 pg/mL), a difference that is statistically highly significant (P = .004). CONCLUSIONS: These findings support heparanase up-regulation in tongue cancer and raise the possibility of using this simple test as a diagnostic tool to monitor tongue cancer progression and response to treatment. 2007 American Cancer Society
Authors: Israel Vlodavsky; Phillip Beckhove; Immanuel Lerner; Claudio Pisano; Amichai Meirovitz; Neta Ilan; Michael Elkin Journal: Cancer Microenviron Date: 2011-08-03
Authors: Uri Barash; Victoria Cohen-Kaplan; Ilana Dowek; Ralph D Sanderson; Neta Ilan; Israel Vlodavsky Journal: FEBS J Date: 2010-08-31 Impact factor: 5.542
Authors: Esti Cohen; Ilana Doweck; Inna Naroditsky; Ofer Ben-Izhak; Ran Kremer; Lael A Best; Israel Vlodavsky; Neta Ilan Journal: Cancer Date: 2008-09-01 Impact factor: 6.860
Authors: Adi Binder Gallimidi; Stuart Fischman; Brurya Revach; Raanan Bulvik; Alina Maliutina; Ariel M Rubinstein; Gabriel Nussbaum; Michael Elkin Journal: Oncotarget Date: 2015-09-08